IN8bio, Inc.
INAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | 1.56 | -0.69 | -3.58 |
| FCF Yield | -5.87% | -1.94% | -1.91% | -0.56% |
| EV / EBITDA | -14.66 | -44.35 | -52.55 | -169.34 |
| Quality | ||||
| ROIC | -151.73% | -101.70% | -99.70% | -35.55% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 0.78 | 0.85 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -1.31% | 13.97% | -101.38% | -93.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.22 | 0.60 | 0.45 | 2.40 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -53.48 | -134.85 | -691.94 | -574.40 |